Literature DB >> 157806

Restoration of cyclophosphamide-induced suppression of thymus-derived cytotoxic cell generation by normal thymocytes.

V J Merluzzi, R B Faanes, Y S Choi.   

Abstract

Spleen cells from mice treated with cyclophosphamide (100 to 200 mg/kg) were unable to generate effective cytotoxic thymus-derived cells to allogeneic tumor cells in vitro. The inability of lymphoid cells from cyclophosphamide-treated mice to generate thymus-derived cytotoxic cells became more apparent as the number of responding cells became limited. This depressed response was not due to the elimination of cytotoxic precursor cells since normal response levels were restored by the addition of thymus cells. The added thymus cells did not provide cytotoxic cells in the culture. The thymus cells active in restoring cytotoxic activity were sensitive to mitomycin C, cyclophosphamide, and anti-theta serum and complement. In addition, the active thymus cells were located in the cortisone-resistant pool and did not adhere to nylon wool columns.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 157806

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Chemoimmunotherapeutic effect of cyclophosphamide on the highly metastatic MAT 13762 tumor.

Authors:  D S Hoon; I A Ramshaw
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

2.  The effects of cyclophosphamide on in vitro cytotoxic responses to a syngeneic tumour.

Authors:  E J Hancock; D G Kilburn
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

3.  The effect of cyclophosphamide on cytotoxic T-lymphocyte responses: inhibition of helper T-cell induction in vitro.

Authors:  K Varkila; M Hurme
Journal:  Immunology       Date:  1983-03       Impact factor: 7.397

4.  In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.

Authors:  S Peppoloni; B J Mathieson; R B Herberman; R W Overton; E Gorelik
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.